First Time Loading...

Stratec SE
XETRA:SBS

Watchlist Manager
Stratec SE Logo
Stratec SE
XETRA:SBS
Watchlist
Price: 40.2 EUR -5.19%
Updated: Mar 29, 2024

Intrinsic Value

STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. [ Read More ]

The intrinsic value of one SBS stock under the Base Case scenario is 71.24 EUR. Compared to the current market price of 40.2 EUR, Stratec SE is Undervalued by 44%.

Key Points:
SBS Intrinsic Value
Base Case
71.24 EUR
Undervaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Stratec SE

Backtest SBS Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SBS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Stratec SE

Current Assets 222.4m
Cash & Short-Term Investments 20.1m
Receivables 62.5m
Other Current Assets 139.8m
Non-Current Assets 220.7m
Long-Term Investments 3.5m
PP&E 81.4m
Intangibles 119.4m
Other Non-Current Assets 16.4m
Current Liabilities 97.7m
Accounts Payable 14.3m
Other Current Liabilities 83.4m
Non-Current Liabilities 119.6m
Long-Term Debt 95.1m
Other Non-Current Liabilities 24.4m
Efficiency

Earnings Waterfall
Stratec SE

Revenue
254.7m EUR
Cost of Revenue
-194.5m EUR
Gross Profit
60.1m EUR
Operating Expenses
-41.1m EUR
Operating Income
19m EUR
Other Expenses
-7m EUR
Net Income
12m EUR

Free Cash Flow Analysis
Stratec SE

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SBS Profitability Score
Profitability Due Diligence

Stratec SE's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Negative Free Cash Flow
Positive Operating Income
51/100
Profitability
Score

Stratec SE's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

SBS Solvency Score
Solvency Due Diligence

Stratec SE's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
High Altman Z-Score
52/100
Solvency
Score

Stratec SE's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SBS Price Targets Summary
Stratec SE

Wall Street analysts forecast SBS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SBS is 53.27 EUR with a low forecast of 40.4 EUR and a high forecast of 81.9 EUR.

Lowest
Price Target
40.4 EUR
0% Upside
Average
Price Target
53.27 EUR
33% Upside
Highest
Price Target
81.9 EUR
104% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

SBS Price
Stratec SE

1M 1M
-4%
6M 6M
-9%
1Y 1Y
-36%
3Y 3Y
-64%
5Y 5Y
-29%
10Y 10Y
+45%
Annual Price Range
40.2
52w Low
37
52w High
68.2
Price Metrics
Average Annual Return 18.58%
Standard Deviation of Annual Returns 54.41%
Max Drawdown -74%
Shares Statistics
Market Capitalization 488.7m EUR
Shares Outstanding 12 155 944
Percentage of Shares Shorted
N/A

SBS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Stratec SE Logo
Stratec SE

Country

Germany

Industry

Health Care

Market Cap

488.7m EUR

Dividend Yield

2.23%

Description

STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg and currently employs 1,398 full-time employees. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

Contact

BADEN-WUERTTEMBERG
BIRKENFELD
Gewerbestr. 37
+49708279160.0
https://www.stratec.com/

IPO

1998-08-25

Employees

1 398

Officers

Chairman of Board of Management & CEO
Mr. Marcus Wolfinger
Director of Finance & Human Resources and Member of Board of Management
Dr. Robert Siegle
Director of Product Development & Member of Board of Management
Dr. Claus Vielsack
Founder & Advisor
Mr. Hermann Leistner
Member of Management Board
Dr. Georg Bauer
Head of Investor Relations, Sustainability & Corporate Communications
Mr. Jan Keppeler
Show More
Head of Supply Chain Management & Senior VP
Mr. Roland Utz
Show Less

See Also

Discover More
What is the Intrinsic Value of one SBS stock?

The intrinsic value of one SBS stock under the Base Case scenario is 71.24 EUR.

Is SBS stock undervalued or overvalued?

Compared to the current market price of 40.2 EUR, Stratec SE is Undervalued by 44%.